Ovid Therapeutics (OVID) Intangibles (2016 - 2022)

Ovid Therapeutics (OVID) has reported Intangibles for 7 consecutive years, with $244000.0 the latest figure, recorded in Q1 2022.

• For the quarter ending Q1 2022, Intangibles fell 7.22% year-over-year to $244000.0; the trailing twelve-month figure through Mar 2022 stood at $244000.0 (down 7.22% YoY), and the FY2021 full-year result was $263000.0, down 17.55% from the prior year.
• Intangibles eased to $244000.0 in Q1 2022 per OVID's latest filing, from $263000.0 in the prior quarter.
• Across five years, Intangibles topped out at $467000.0 in Q4 2019 and bottomed at $160390.0 in Q1 2018.
• Historically, Intangibles has averaged $316341.2 across 5 years, with a median of $319000.0 in 2020.
• The sharpest annual moves came in 2018 and 2021: Intangibles jumped 234.71% in 2018, then slumped 45.43% in 2021.
• Over 5 years, Intangibles stood at $392000.0 in 2018, then gained by 19.13% to $467000.0 in 2019, then slumped by 31.69% to $319000.0 in 2020, then retreated by 17.55% to $263000.0 in 2021, then dropped by 7.22% to $244000.0 in 2022.
• According to Business Quant data, Intangibles over the past three periods registered $244000.0, $263000.0, and $197000.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.